{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-048971","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.235881+00:00","generated_at":"2026-05-15T03:45:49.834834+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026","bullets":["Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.","Phase 3 U.S. trial of denifanstat in moderate-to-severe acne planned for H2 2026, pending IND clearance.","MASH development paused until non-dilutive funding secured; combination program with resmetirom ready for Phase 2.","New CMO Andreas Grauer appointed; Phase 1 of TVB-3567 ongoing, Phase 2 acne trial targeted for H2 2026.","Positive Phase 3 acne safety results from partner Ascletis in China reported Jan 2026 (n=240)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-048971","json":"https://secwatch.observer/filing/0001104659-26-048971.json","markdown":"https://secwatch.observer/filing/0001104659-26-048971.md","text":"https://secwatch.observer/filing/0001104659-26-048971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/0001104659-26-048971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:45:49.834834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6d676f48b99577280026e4406fe848eb2e9b149","claim":"Sagimet Biosciences Inc. reported preliminary financial results for the Company’s fiscal quarter ended March 31, 2026.","evidence_excerpt":"Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/0001104659-26-048971-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the Company’s fiscal quarter ended March 31, 2026"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}